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The immunosuppressive qualities and other features 
of a new cyclosporine (CsA) analogue, Nva2-cyclospor-
ine (Nva2-CsA) were examined using canine orthotopic 
liver allografts. The mean survival time was 11.8±9.6 
(SD) days in dogs without treatment, 60.8±34.4 days 
with Nva2 -CsA and 65.1±33.0 days with CsA. Func-
tional abnormalities indicating toxic side effects were 
not noted either with Nva2-CsA or with CsA. Using the 
same oral dose, the rate of blood level rise and the 
amount of the rise were greater with Nva2 -CsA. Histo-
pathologically, Nva2 -CsA treatment was associated with 
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the same degree of hydropic vocuolation in the pars recta 
of the proximal tubules as CsA treatment. Thus, in the 
dog, Nva2 -CsA had identical immunosuppressive prop-
erties as CsA, with no functionally detectable toxicity 
affecting the liver and kidney. 
The most limiting side effects of the new immunosuppressive 
agent, cyclosporine (CSA),3 have been from nephrotoxicity (1-
3). Consequently, the announcement in 1984 of a cyclosporine 
analogue, hereafter called Nva2-cyclosporine (Nva2-CsA), 
which was not nephrotoxic (4), attracted more than casual 
3 Abbreviations used: BIB, beagle-to-beagle; BUN, blood urea nitro-
gen; Cr, creatinine; CsA, cyclosporine; CsD, cyclosporine D; D-bili, 
direct bilirubin; MIB, mongrel-to-beagle; SGOT, serum glutamic oxalo-
acetic transaminase; T -bili, total bilirubin. 
March,1986 TODO ET AL. 297 
interest. Nva2-CsA was shown by Hiestand et al. (4) to have 
potent immunosuppressive qualities in rats. 
In this report, we will describe the immunosuppressive qual-
ities and other features of Nva2-CsA in comparison to those of 
CsA in canine recipients of orthotopic liver homografts. In 
addition, particular attention was paid to the histopathologic 
changes or lack thereof denoting nephrotoxicity in the kidneys 
of dogs treated with one or the other of these agents for 90 
days, or for lesser periods in the event of earlier death. 
The results have shown that Nva2-CsA has immunosuppres-
sive properties equal to those of CsA. Neither drug caused 
detectable changes in renal function but the use of both agents 
was associated with an equal amount of histologically demon-
strable hydropic change in the renal tubules. 
MATERIALS AND METHODS 
Female beagle and mongrel dogs, weighing 10-15 kg, were 
obtained from the University animal farm. Beagle-to-beagle 
(B/B)4 or mongrel-to-beagle (MIB) combinations were used. 
On the morning of operation, the dogs were not fed and were 
anesthetized with sodium pentobarbital and ketamine. The 
donor was exsanguinated during removal of the liver and the 
blood was stored for transfusions. Usually, no other blood was 
given. The principles of the transplantation were as described 
before (5) but with several important modifications. Low flow 
venovenous bypasses (6) were used to decompress the portal 
and systemic venous systems during the anhepatic period while 
the liver was orthotopically transplanted. Drainage of the 
splanchnic bed during bypass was through the splenic vein after 
splenectomy. Drainage of the inferior vena caval bed was 
through the femoral vein, and pump driven delivery of the 
blood was to the external jugular vein. The suprahepatic vena 
caval, infrahepatic vena caval, and portal venous reconstruc-
tions were with end-to-end anastomoses. Hepatic arterial flow 
was restored with an end-to-side anastomosis of the donor to 
recipient abdominal aorta (5, 6). The biliary tract was recon-
structed with cholecystoduodenostomy after ligation of the 
common duct. Antibiotics were given for 3 days. Oral intake, 
including CsA or Nva2-CsA was started on the morning after 
operation. 
Both CsA and Nva2-CsA were supplied" as a powder. They 
were dissolved in ethanol and in olive oil to a concentration of 
100 mg/ml of solution. One or the other drug was randomly 
selected for a given dog on the morning after operation and 
given orally in doses of 20 mg/kg body weight on that morning 
and daily for the first 30 days. Then the doses were reduced to 
15 mg/kg. The drug was discontinued after the 90th postoper-
ative day or earlier in 2 dogs for which there was not sufficient 
Nva2-CsA. 
A total of 46 liver transplantations were performed. Animals 
that did not survive for 6 days or more were excluded from 
analyses in order to eliminate the artifact introduced by lethal 
technical and surgical complications. To obtain 19 dogs which 
survived 6 days or more in the immunosuppressed groups, 27 
transplantations were required for an inclusion rate of 70%. In 
contrast, 19 transplantations were required in untreated dogs 
to obtain 8 6-day survivors for an inclusion rate of only 42%. 
The culled final groups were as follows: 
Group I-no treatment, 8 dogs; 6 were BIB and 2 were 
M/B. 
Group 2-Nva2-CsA, 10 dogs; 5 were BIB and 5 were MIB. 
Group 3-CsA, 9 dogs; 4 were BIB and 5 were MIB. 
• Sandoz Corporation, Basel, Switzerland. 
Morning blood samples were taken every 3 days postopera-
tively and analyzed for serum glutamic oxaloacetic transami-
nase (SGOT), total bilirubin, and direct bilirubin (T- and D-
bili), blood urea nitrogen (BUN) and creatinine (Cr). The blood 
concentrations of CsA and Nva2-CsA were measured with hep-
arinized blood by high-performance liquid chromatography us-
ing cyclosporine D (CsD) as a standard for CsA determination 
and CsA as an internal standard for Nva2-CsA measurements. 
In addition, tissue distributions and concentrations of Nva2-
CsA and CsA were measured in specimens frozen at -20·C 
after sampling at biopsy or autopsy. These studies are reported 
elsewhere. 
At the end of 90 days, all surviving dogs underwent unilateral 
nephrectomy and liver biopsy. Specimens were fixed in 4% 
phosphate buffered formalin and in 2.5% cacodylate-buffered 
glutaraldehyde for light microscopic and electron microscopic 
examinations, respectively. Animals that died before 90 days 
were autopsied as soon as possible and the tissues were fixed 
in formalin. Structural changes were graded according to se-
verity on a subjective 0 to +++ scale. 
Statistics were performed using Students t test, Chi square 
test, or Fisher's exact test. Group means were considered sig-
nificantly different if probability of error was less than 0.05. 
RESULTS 
The results with the two donor-to-recipient strain combina-
tions, BIB and M/B, were not statistically significantly differ-
ent. Therefore, these were pooled in all 3 of the groups. 
Survival. Of the 8 control animals, 7 died within 19 days. 
The eighth dog survived for 35 days; this was a BIB strain 
combination. Mean survival was 1l.8±9.6 (SD) days (Fig. 1). 
In the treated dogs, an arbitrary observation limit of 90 days 
was set in calculating survival. Nva2-CsA administration had 
to be discontinued in two dogs of group 2 after 82 days and 73 
days because of a shortage of the drug. The former animal 
survived for more than 90 days and the latter dog died at 80 
days, 3 days after unilateral nephrectomy. Credit to the time 
points of 90 and 80 days for these 2 dogs were used in the 
calculation of survival. 
Using a ceiling of 90 days for calculation, dogs in group 2 
(Nva2-CsA) lived for a mean of 60.8±34.4 (SD) days, and those 
in group 3 (CsA) lived for 65.1±33 (SD) days (Fig. 1). At 30, 
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FIGURE 1. Survival of group 1 (control), group 2 (Nva2-CsA), and 
group 3 (CsA) animals after orthotopic liver transplantation. Differ-
ences between group 2 and group 3 are not significant. 
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60, and 90 days, the survival rates in the group 2 dogs (Nva2-
CsA) and the group 3 animals (CsA) were 70 versus 67, 60 
versus 67, and 40 versus 56. The differences were not signifi-
cant. 
At the end of 90 days, 9 dogs were still alive, 4 from group 2 
(Nva2-CsA) and 5 from group 3 (CsA). Four were B/B and 5 
were M/B stain combinations. Therapy was stopped. Five dogs 
died subsequently after a total survival of 94 (CsA), 118 (Nva2-
CsA), 122 (CsA), 123 (Nva2-CsA), and 138 (CsA) days. All 5 
animals had progressive hepatic failure. Histopathologic ex-
amination of their livers at autopsy compared with the livers 
at the 90-day biopsy showed a striking reduction in the number 
of small bile ducts, an increase in the amount of collapse of the 
reticulin fibrils at the center of the lobular framework, forma-
tion of septa linking portal tracts and cutting across lobules, 
and the appearance of cholestasis. 
Four dogs are still living after discontinuance of therapy with 
Nva2-CsA (2 dogs) or CsA (2 dogs). All four were M/B. The 
longest survival (Nva2-CsA) is now 241 days. 
Hepatic and renal function. In the untreated controls, abrupt 
elevations of SGOT and T-bili and D-bili were observed be-
tween the fourth and the sixth postoperative days (Fig. 2). This 
acute deterioration of liver function caused by rejection led 
eventually to the death of all animals. In contrast, the SGOT 
of animals treated either with Nva2-CsA or CsA showed only 
moderate abnormalities that tended to stabilize (Fig. 3). There 
were 3 animals in group 2 (Nva2-CsA) and 4 in group 3 (CsA) 
that survived for 90 days with only slight or no elevations of 
bilirubin throughout this time (Fig. 4). The other long-surviving 
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FIGURE 2. Changes in SGOT and T -bili of untreated control ani-
mals after liver transplantation. 
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FIGURE 3. Changes in SGOT of group 2 (Nva2-CsA) and group 3 
(CsA) animals after liver transplantation. 
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FIGURE 4. Changes in T-bili of group 2 (Nva2-CsA) and group 3 
(CsA) animals after liver transplantation. 
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FIGURE 5. Changes in the blood level of Nva2-CsA (group 2) and 
CsA (group 3) after liver transplantation. Shaded zone indicates mean 
values. 
dogs had variable jaundice in spite of continuous therapy. No 
significant changes in Cr and BUN were noted in the control, 
Nva2-CsA or CsA animals. 
Cyclosporine blood levels. The whole-blood levels of cyclo-
sporine measured with high-performance liquid chromatogra-
phy varied considerably in individual dogs. However, the mean 
blood level of cyclosporine in the Nva2-CsA-treated animals of 
group 2 was higher than in the CsA-treated dogs of group 3 at 
all postoperative intervals (Fig. 5). The differences were signif-
icant at 36, 57, 63, 66, 69, 81, 84, and 87 days. A reduction of 
dose from 20 mg/kg to 15 mg/kg caused no decline of the blood 
level in either group, but 2 Nva2-CsA dogs (Fig. 6) and 1 CsA 
dog died of rejection after this reduction (Fig. 6). 
The average 24-hr trough level of cyclosporine throughout 
treatment with Nva2 -CsA was 409.4 ng/ml (range 25-2240) 
compared with 235.8 ng/ml (range 25-935) during treatment 
with CsA, a difference that was highly significant. The number 
of dogs that had an average value more than 500 ng/ml was 3 
in the Nva2-CsA group and none in the CsA group (Fig. 7). The 
interval for the mean level to rise to 200, 300, and 400 ng/ml 
after transplantation was 9, 12, and 21 days in group 2 (Nva2-
CsA) compared with 12,21, and 27 days in group 3 (CsA) (Fig. 
5). Thus, the rate of postoperative blood level rise as well as 
the amount of the rise was greater in group 2. 
The animals in both group 2 and group 3 that had blood 
levels averaging more than 200 ng/ml survived for significantly 
longer periods than those with lower levels, and they had lower 
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FIGURE 6. Changes in Nva2-CsA dose, blood level, T-bili, and SGOT 
of No. 30 dog (group 2). Despite no appreciable change of blood Nva2-
CsA level after dose reduction, the animal died of rejection. 
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FIGURE 7. Correlations of trough blood level of Nva2-CsA (open 
circle) and CsA (black box) with the survival, average T-bili, and 
average creatinine of each animaL 
concentrations of serum bilirubin and SGOT but did not show 
significant correlations with Cr (Fig. 7). Animals with low blood 
cyclosporine levels commonly had significant body weight loss, 
probably reflecting poor control of rejection. 
Pathologic studies. All but one of the control untreated ani-
mals showed acute rejection of the liver allograft. In the ex-
panded portal tracts, there was dense mononuclear cell infiltra-
tion, particularly around the smaller bile ducts and portal vein 
branches. Blast cells and mitoses were frequent. Small bile duct 
epithelium was damaged, and hepatocytes in the central parts 
of the lobules were atrophic. In the two animals that survived 
for 19 days and 35 days, respectively, many of the smaller bile 
ducts had been destroyed and there was collapse of the reticulin 
fibril framework around central veins. The one exception was 
an animal that died at six days from acute renal tubular 
necrosis. In this dog, mild mononuclear cell infiltration of the 
portal tracts was the only abnormality. 
The CsA and Nva2-CsA-treated liver allografts also showed 
mononuclear cell infiltration of portal tracts, but this was less 
severe and there were fewer blast cells. In the nine dogs that 
survived for 90 days, there was also proliferation of bile ductules 
and portal tract fibrosis; these changes were slight in four of 
the animals (two from each group). Disappearance of small bile 
ducts, collapse of the centrilobular recticulin fibrils, septa link-
ing portal tracts and cutting across lobules, destruction of the 
limiting plates, and atrophy of centrilobular hepatocytes and 
cholestasis were striking additional features of the five liver 
allografts that survived for 18-88 days after discontinuance of 
therapy. All of these animals died as a result of this chronic 
rejection. The death of a CsA-treated dog at 8 days was due to 
hepatic artery thrombosis. The Nva2-CsA dog that died at 9 
days had destroyed its graft by a combination of acute rejection 
and suppurative cholangitis; an animal that survived for 11 
days perished from peritonitis with minor changes in the graft. 
In the treated animals, there was no structural evidence to 
suggest additional damage to the liver allograft by either CsA 
or Nva2-CsA. 
Hydropic vacuoles were found in the cytoplasm of the pars 
recta of the proximal convoluted tubules in kidneys from dogs 
in all three groups. Inclusion bodies and microcalcification were 
not seen. These changes were more common in the two treated 
groups, affecting 75% of the kidneys from the animals given 
CsA and 80% of the kidneys from the Nva2-CsA group, com-
pared with 38% of the kidneys from the control dogs. The 
juxtaglomerular apparatus, which was normal in the controls, 
was enlarged with increased numbers of granular cells in 75% 
of the kidneys from the dogs treated with Nva2-CsA and in 
40% of those given CsA. Small electron-dense deposits were 
present in the glomerular mesangium of 80% of the dogs treated 
for 90 days with Nva2-CsA, and 60% of those treated for a 
similar period with CsA. Mesangial deposits were also present 
in the two controls that survived for 19 and 35 days, respec-
tively. There were no arteriolar changes. 
DISCUSSION 
Both Nva2-CsA and CsA are produced by the fungus Toly-
pocladium inflatum GAMS. The Nva2-CsA differs in structure 
from CsA only in that nonvaline is in position 2 of the cyclic 
endecapeptide instead of an alpha-amino butyric acid residue 
(4). Good immunosuppression of Nva2-CsA in rats was docu-
mented by Hiestand et al. (4), an effort that has not yet been 
made in larger animals. The provision of such information was 
the main purpose of the present investigation in dogs. 
The strain combinations used in these studies provided some 
advantages as well as disadvantages. The principal advantage 
was a closer genetic control with a presumed smaller variance 
in immunologic response. The principal disadvantage could 
have been that the BIB combination may be "too easy." In 
actual fact, the results with the BIB or M/B strain combina-
tions were not significantly different. It was noteworthy that 
all 4 of the dogs with long survival after discontinuance of drug 
therapy were from the presumably less-favorable M/B combi-
nation. The results with either Nva2-CsA or CsA were remark-
ably good, with survival of more than 60 days even when credit 
for a maximum of 90 days was the limit for any individual dog. 
Thus, there were neither any subtle or obvious differences 
between Nva2-CsA and CsA in terms of immunosuppression. 
The evidence that Nva2-CsA is nonnephrotoxic so far has 
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come from studies in strains of rats that develop renal disease 
or spontaneous hypertension (7). The backdrop of incipient 
kidney damage apparently has been important in unmasking 
the additional nephrotoxicity that is imposed with CsA. In such 
test systems, Nva2-CsA has not caused or amplified kidney 
damage (7). 
It was recognized in advance that the dog was an inappro-
priate experimental animal in which to compare the nephro-
toxicity of Nva2-CsA with CsA. Neither drug ever caused an 
increase in BUN or Cr. The majority of the kidneys from 
animals treated with either CsA or Nva2-CsA showed hydropic 
vacuolation of the epithelium lining the pars recta or straight 
part of the proximal tubules. Comparable lesions were far less 
frequent in the controls. This part of the canine tubule is the 
equivalent of the S2 and S3 segment of the rat tubule where 
vacuolation is characteristically found after high doses of CsA 
(8). The mesangial electron dense deposits possible resulted 
from gut-derived antigens or complexes reaching the circulation 
in excessive quantities because of either defective reticuloen-
dothelial activity or spontaneously developing portal-systemic 
shunts in the liver recipients. 
Thus, the question of nephrotoxicity will have to be clarified 
in other experimental situations and presumably in animals 
other than dogs. For the moment, it may be said that Nva2-
CsA has immunosuppressive qualities as impressive as those of 
CsA. From the results, further clarification of the pharmaco-
kinetics of Nva2-CsA versus CsA will be important. It is sug-
gested that Nva2-CsA is more effectively absorbed, since the 
average blood levels were somewhat greater than with the 
administration of CsA. The implication of this latter finding is 
not yet clear-although it may be important, since in both the 
Nva2-CsA and CsA-treated animals there was a definite, al-
though imperfect, positive correlation between the blood levels 
of the drug, the quality of graft function, survival, and the 
ability to maintain weight and good health. 
Note added in proof After the manuscript for this article was 
submitted, a study of Nva2-CsA in dogs with kidney transplan-
tation was reported by CaIne et. al. in a Letter to the Editor of 
Lancet (1985; 2: 1342-1343). The conclusion of the English 
group-that Nva2-CsA is more immunosuppressive and less 
nephrotoxic than CsA-could not be supported from our ex-
periments with a different kind of graft. 
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